Literature DB >> 31454825

Identification of Genes and Pathways Associated with Acne Using Integrated Bioinformatics Methods.

Xianglan Li1, Yuxi Jia1, Shiyi Wang1, Tianqi Meng1, Mingji Zhu2.   

Abstract

BACKGROUND: Acne is the most common skin inflammatory condition. The pathogenesis of acne is not fully understood. AIMS: We performed weighted gene co-expression network analysis (WGCNA) to select acne-associated genes and pathways.
METHODS: GSE53795 and GSE6475 datasets including data from lesional and nonlesional skin of acne patients were downloaded from the NCBI Gene Expression Omnibus. Differentially expressed genes (DEGs) in lesions were identified following a false discovery rate <0.05 and | log2 fold change | ≥0.5. DEG-associated biological processes and pathways were identified. WGCNA analysis was performed to identify acne-associated modules. DEGs in the acne-associated modules were used for protein-protein interaction (PPI) network construction and Gene Set Enrichment Analysis (GSEA). Acne-associated candidate DEGs and pathways were identified together with items in the Comparative Toxicogenomics Database (CTD).
RESULTS: A total of 2,140 and 1,190 DEGs were identified in GSE53795 and GSE6475 datasets, respectively, including 716 overlapping DEGs with similar expression profiles in the two datasets, which were clustered into 10 consensus modules. Two modules (brown and turquoise, 359 genes) were associated with acne phenotype. Of these 359 DEGs, 254 were enrolled in the PPI network. GSEA showed that these DEGs were associated with chemokine signaling pathway, cytokine-cytokine receptor interaction, and natural killer cell-mediated cytotoxicity. After identification in CTD, one pathway Cytokine-cytokine receptor interaction and 24 acne-associated DEGs, including IL1R1, CXCL1, CXCR4, CCR1, CXCL2 and IL1β, were identified as candidates associated with acne.
CONCLUSION: Our results highlight the important roles of the proinflammatory cytokines including IL1β, CXCL1, CXCL2, CXCR4, and CCR1 in acne pathogenesis or therapeutic management.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Acne; Inflammation; Microarray data; Pathway; Weighted gene co-expression network analysis

Mesh:

Substances:

Year:  2019        PMID: 31454825     DOI: 10.1159/000502203

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  6 in total

1.  Altered Gene Expression in Acne Vulgaris Patients Treated by Oral Isotretinoin: A Preliminary Study.

Authors:  Yue Zheng; Wei Lai; Yuchen Jiang; Haiyan Chen; Le Han; Xiaoyuan Xie
Journal:  Pharmgenomics Pers Med       Date:  2020-09-15

2.  Characterization of a Cutibacterium acnes Camp Factor 1-Related Peptide as a New TLR-2 Modulator in In Vitro and Ex Vivo Models of Inflammation.

Authors:  Constance Mayslich; Philippe Alain Grange; Mathieu Castela; Anne Geneviève Marcelin; Vincent Calvez; Nicolas Dupin
Journal:  Int J Mol Sci       Date:  2022-05-03       Impact factor: 6.208

3.  Use of bioinformatic analyses in identifying characteristic genes and mechanisms active in the progression of idiopathic thrombocytopenic purpura in individuals with different phenotypes.

Authors:  Mengyi Zhang; Binhan Guo
Journal:  J Int Med Res       Date:  2020-11       Impact factor: 1.671

4.  PEG-8 Laurate Fermentation of Staphylococcus epidermidis Reduces the Required Dose of Clindamycin Against Cutibacterium acnes.

Authors:  Shinta Marito; Sunita Keshari; Chun-Ming Huang
Journal:  Int J Mol Sci       Date:  2020-07-19       Impact factor: 5.923

5.  Gene variants associated with acne vulgaris presentation and severity: a systematic review and meta-analysis.

Authors:  Anna Hwee Sing Heng; Yee-How Say; Yang Yie Sio; Yu Ting Ng; Fook Tim Chew
Journal:  BMC Med Genomics       Date:  2021-04-13       Impact factor: 3.063

6.  The immunomodulatory potential of phage therapy to treat acne: a review on bacterial lysis and immunomodulation.

Authors:  Juan Farfán; John M Gonzalez; Martha Vives
Journal:  PeerJ       Date:  2022-07-25       Impact factor: 3.061

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.